Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Los Angeles, California 90048


Purpose:

Healthy pre-menopausal women will be recruited in order to test the effects of red wine and white wine on blood estrogen and progesterone levels. The women will be randomized and rotated through two different treatments (red wine, white wine). Estrone and estradiol are hormones in the category of estrogens. It is known that the bodies of both men and women may convert (or aromatize) a certain amount of naturally occurring testosterone into estrogen. Aromatase inhibitors have been used to prevent this conversion, or aromatization, of testosterone into estrogen, in the treatment of estrogen-dependent breast cancer in women. This inhibition leads to a marked decrease in estrogen (estradiol and estrone) levels. Naturally occurring aromatase inhibitors include grapes, grape juice, and red, but not white wine. The aromatase inhibitory effects are attributed to wine phytochemicals and not to alcohol. Based upon this information, the investigators will monitor the estrogen levels at various phases in the menstrual cycles of women since hormone levels naturally vary throughout the menstrual cycle. Several epidemiologic studies have found that there is a correlation with moderate to high levels of alcohol consumption and breast cancer. Therefore, study participants will be asked to drink only a eight ounces of wine which should have minimal or no risk for the development of breast cancer.


Criteria:

Inclusion Criteria: 1. female 2. pre-menopausal with regular ovulatory cycles for 12 months prior to the study 3. willingness and ability to participate in study requiring alcohol consumption 4. in general good health 5. BMI of 18.5-35 6. on regular, unrestricted diet 7. not currently, or within the past 3 months, using oral contraceptives or other hormone replacement therapy Exclusion Criteria: 1. male 2. irregular menstrual cycles or vasomotor symptoms within the last 12 months 3. pregnant (or breast feeding) 4. any hormone therapy including phytoestrogens, oral contraceptives, SERMs, or androgens (or precursors) for three months prior to the study 5. history of alcohol abuse 6. history of any estrogen-dependent neoplasia 7. high intake of dietary soy products 8. Minors < age 21 years


NCT ID:

NCT00572351


Primary Contact:

Principal Investigator
Glenn D Braunstein, MD
Cedars Sinai Medical Cneter


Backup Contact:

N/A


Location Contact:

Los Angeles, California 90048
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 17, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.